NCT07128082Active, not recruitingPhase 2
The Long COVID Treatment Trial
Source: ClinicalTrials.gov · Last updated 23 Dec 2025
Brief summary (registry, in English)
The goal of this study is to determine whether a medicine called tirzepatide, also called Zepbound, can reduce symptoms of Long COVID. A randomized control trial will allow us to measure the effect of the treatment by having half of the participants take the medication and half take a placebo that has no medication. Participants will take the medication (or placebo) they are given and complete study surveys for 12 months. All of the study tasks are done remotely from the comfort of a participants home.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 1000 (actual)
- First submitted
- 14 Aug 2025
- Start date
- 30 Oct 2025
- Primary completion date
- Dec 2026
- Lead sponsor
- Scripps Translational Science Institute
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT07128082
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 1000
- From 30 Oct 2025 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Medication contraindications to tirzepatide
- Planning to undergo elective surgery or procedures requiring general anesthesia or deep sedation in the next 12 months
Other illness
- Personal or family history of medullary thyroid carcinoma
- History of severe gastrointestinal disease
- Worsening or chronic renal failure
- History of pancreatitis
- Multiple Endocrine Neoplasia syndrome type 2
- Known serious hypersensitivity to tirzepatide
- History of suicidal attempts and/or active suicidal ideation
- Symptoms of fatigue and/or brain fog that predated infection with COVID-19
Other
- Certain vulnerable populations (prisoners, children, fetuses, and institutionalized individuals)
- Women who are pregnant, excluded due to unknown risks to a fetus
- Diagnosis of gastroparesis
- Already taking tirzepatide or another GLP-1 agonist
- Underweight (BMI under 18.5)
Who the study is looking for
- 18 years of age or older Living in the United States Able to read and understand English or Spanish Willing and able to participate in study interventions and activities, including;
- Access to an internet connected device
- Informed Consent
- Surveys
- Medication schedule
- Adverse Event reporting
- Weight reporting
- Use of wearable activity tracker
- Completing at home blood collections, if selected Meets the NASEM definition of Long COVID: an infection-associated chronic condition that occurs after SARS-CoV-2 infection and is present for at least 3 months as a continuous, relapsing and remitting, or progressive disease state that affects one or more organ systems 16.
- Ability to verify identity Ability to verify diagnosis Agree to notify the study team if you start any other Long COVID treatments while enrolled in the study.
- Complete the Fatigue Severity Scale with a minimum score of 36
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Scripps Research Coordinator of this site? Confirm its status | La Jolla | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.